Highlights & Summary

Major acquisitions and mega-rounds led May. Roche agreed to buy digital-pathology company PathAI for up to $1.05 billion, the largest AI-pathology deal to date, while Isomorphic Labs raised a $2.1 billion Series B to scale its AI drug-design platform. In diagnostics, the FDA cleared two AI tools: Tempus's tumor-only xT CDx and Artera's ArteraAI Breast, the first AI digital-pathology risk test for breast cancer. Health systems and payers kept moving from pilots to enterprise rollouts, with Bristol Myers Squibb adopting Claude Enterprise across its operations, Cedars-Sinai deploying OpenEvidence system-wide inside Epic, and UnitedHealthcare pledging to cut prior authorizations by roughly another 30% in 2026 as Cohere Health backed CMS's push to standardize electronic prior authorization.

‍

Headlines

AI in Drug Discovery  

1 | Isomorphic Labs Raises $2.1B Series B to Scale Its AI Drug Design Engine | Financing

2 | Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Deploy Claude Enterprise Across Its Global Operations | Partnership

3 | Biohub Releases a World Model of Protein Biology | New Product

4 | Owkin to Build AI Agents in a Multi-Year K Pro Collaboration with Sanofi | Partnership

5 | Perceptic Emerges from Stealth with $12M Seed to Automate Drug Discovery End-to-End for Big Pharma | Company Creation

‍

‍

‍

AI in Diagnostics  

1 | Roche to Buy AI Pathology Company PathAI in Deal Worth Up to $1.05B | M&A

2 | Scanner Maker Grundium Acquires Pathology-AI Firm Visiopharm to Offer a Combined Platform | M&A

3 | Tempus Wins FDA Approval for a Tumor-Only Version of Its xT CDx Test | Regulatory

4 | FDA Clears Artera's AI Tool That Scores Breast-Cancer Risk from Pathology Slides | Regulatory

5 | Mayo Clinic's AI Spots Pancreatic Cancer on Routine CT Scans Long Before It's Diagnosed | New Research

‍

‍

AI in Healthcare  

1 | Cedars-Sinai Rolls Out OpenEvidence System-Wide, Linking Clinical AI to Patient Records in Epic | Partnership

2 | Commure Lands $200M from General Catalyst to Expand AI Revenue-Cycle and Agent Tools | Financing

3 | Cohere Health Backs New CMS Push to Make Electronic Prior Authorization Work End-to-End | Partnership

4 | UnitedHealthcare Pledges to Cut Prior Authorizations by Another Third in 2026 | Commercial

5 | Large Multisite Study Ties AI Scribes to Modest Time Savings and Slightly Higher Visit Volume | New Research

‍

‍

‍

Summaries

AI in Drug Discovery  

1 | Isomorphic Labs Raises $2.1B Series B to Scale Its AI Drug Design Engine | Financing

Isomorphic Labs, Alphabet's AI-first drug design company, raised $2.1B in a Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The capital will fund continued development of its AI drug design engine (IsoDDE), global expansion of the business, and advancement of its therapeutic pipeline toward the clinic.

2 | Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Deploy Claude Enterprise Across Its Global Operations | Partnership

BMS entered a strategic agreement with Anthropic to deploy Claude Enterprise as a shared intelligence platform for more than 30,000 employees across research, clinical development, manufacturing, commercial, and corporate functions. The rollout prioritizes Claude Code for engineering and data-science teams and embeds agentic workflows into priority use cases such as trial documentation and regulatory submissions, manufacturing root-cause investigation and batch release, and turning field insights into structured intelligence, all under enterprise governance and audit controls.

3 | Biohub Releases a World Model of Protein Biology | New Product

Biohub released what it calls a world model of protein biology: an openly available ecosystem comprising ESMC (a protein language model trained on roughly 2.8B sequences), ESMFold2 (structure prediction and design), and ESM Atlas (a database of 6.8B sequences and 1.1B predicted structures). The tools map proteins across the tree of life, predict their 3D structures, and design new functional binders, with Biohub stating ESMFold2 can compress initial drug-candidate screening from months or years to days. All three are freely available to the global scientific community via the Biohub Platform.

4 | Owkin to Build AI Agents in a Multi-Year K Pro Collaboration with Sanofi | Partnership

Sanofi and Owkin expanded their partnership into a multi-year collaboration to co-develop next-generation biopharma AI agents, backed by a five-year license for Owkin's K Pro platform. The agents are designed to autonomously perform complex R&D tasks spanning early discovery, clinical development, competitive intelligence, and patient positioning, building on a relationship that began with a EUR 90M oncology-focused deal in 2021 and later expanded into immunology drug positioning.

5 | Perceptic Emerges from Stealth with $12M Seed to Automate Drug Discovery End-to-End for Big Pharma | Company Creation

Perceptic, founded in London in 2024 by three former Palantir life-sciences executives, emerged from stealth with a $12M seed round led by Accel, alongside Air Street Capital and Elder Gull. The roughly 20-person company positions its platform as connective tissue linking discrete AI tools to pharma companies' proprietary data across discovery through clinical trial design, and says it is already in use by top-tier pharmas including CSL.

‍

‍

‍

AI in Diagnostics  

1 | Roche to Buy AI Pathology Company PathAI in Deal Worth Up to $1.05B | M&A

Roche signed a definitive merger agreement to acquire digital pathology company PathAI for $750 million upfront plus up to $300 million in milestone payments, the largest deal to date in AI-powered pathology. PathAI's AISight image management platform and its suite of AI biomarker algorithms, covering markers such as PD-L1, HER2, and ER/PR, will join Roche's Diagnostics division and complement its VENTANA staining and scanning portfolio. The transaction builds on a partnership the companies began in 2021 and expanded in 2024 to co-develop companion diagnostic algorithms, and is expected to close in the second half of 2026.

2 | Scanner Maker Grundium Acquires Pathology-AI Firm Visiopharm to Offer a Combined Platform | M&A

Grundium, a Finnish digital-scanning company backed by EW Healthcare Partners, acquired Danish AI pathology software developer Visiopharm for an undisclosed sum. The deal pairs Grundium's compact whole-slide scanners with Visiopharm's image-analysis software, which holds nine diagnostic algorithms cleared under EU IVDR, to create an integrated offering for clinical labs, biopharma, and research. Both products will continue to be sold and supported independently, extending a prior integration partnership between the two companies.

3 | Tempus Wins FDA Approval for a Tumor-Only Version of Its xT CDx Test | Regulatory

Tempus received FDA approval for a tumor-only indication of its xT CDx assay, making it the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. xT CDx is a 648-gene tissue-based test for molecular profiling across solid tumors and serves as a companion diagnostic to identify colorectal cancer patients who may benefit from Erbitux (cetuximab) and Vectibix (panitumumab). The expanded label lets the test run without a matched normal blood or saliva sample and clears the way for Tempus to migrate its full DNA solid-tumor portfolio onto FDA-approved assays.

4 | FDA Clears Artera's AI Tool That Scores Breast-Cancer Risk from Pathology Slides | Regulatory

Artera received FDA 510(k) clearance for ArteraAI Breast, the first FDA-cleared digital pathology-based risk-stratification tool for breast cancer, indicated for early-stage HR+/HER2- invasive disease. The multimodal AI model combines digitized histopathology images with clinical variables to sort patients into low- or high-risk groups for distant metastasis, running on routine surgical resection slides with same-day results and no separate specimen collection. The clearance follows the company's de novo authorization for ArteraAI Prostate in 2025 and is supported by validation across multiple Phase 3 trials, including chemotherapy-benefit findings in the NSABP B-20 cohort.

5 | Mayo Clinic's AI Spots Pancreatic Cancer on Routine CT Scans Long Before It's Diagnosed | New Research

A Mayo Clinic AI model called REDMOD (Radiomics-based Early Detection Model) detected pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, in a validation study published in Gut. Across nearly 2,000 multi-institution scans originally read as normal, REDMOD flagged 73% of prediagnostic cancers at a median of about 16 months before diagnosis, roughly doubling the detection rate of specialists without AI and performing about three times better on scans taken more than two years out. The model extracts hundreds of quantitative texture features and runs automatically on scans taken for other reasons, particularly in high-risk patients such as those with new-onset diabetes; it is now being evaluated prospectively in the AI-PACED study.

‍

‍

AI in Healthcare  

1 | Cedars-Sinai Rolls Out OpenEvidence System-Wide, Linking Clinical AI to Patient Records in Epic | Partnership

Cedars-Sinai gave its physicians, nurses, pharmacists, and therapists enterprise access to OpenEvidence, integrated into Epic so clinicians can ask questions in plain language and get answers drawn from both the medical literature and an individual patient's record, including prior procedures, comorbidities, medications, and allergies. Patient data is used only to inform that session and is not stored by OpenEvidence, and the health system plans to layer its own care pathways and protocols into the platform. The rollout follows comparable Epic integrations at Sutter Health and Mount Sinai earlier in 2026 and reflects a shift toward embedding clinical decision support directly in the workflow.

2 | Commure Lands $200M from General Catalyst to Expand AI Revenue-Cycle and Agent Tools | Financing

Commure raised $200 million in growth financing led by General Catalyst's Customer Value Fund to scale its AI platform for healthcare administration, spanning ambient documentation, agentic workflows, and revenue-cycle automation. The company says its tools run inside more than 500 healthcare organizations across 3,000-plus sites of care and that over 85% of revenue-cycle work is completed without a human in the loop. Athelas operates as a Commure company within the same platform.

3 | Cohere Health Backs New CMS Push to Make Electronic Prior Authorization Work End-to-End | Partnership

Cohere Health endorsed the CMS Health Tech Ecosystem effort and its newly created Electronic Prior Authorization Acceleration initiative, joining health plans and provider groups working to make electronic prior authorization function reliably from end to end. Cohere says its prior-authorization APIs and clinical-intelligence platform handle 47 million payer-provider interactions a year and move patients to care roughly 70% faster than legacy processes. The move positions the company for CMS's January 2027 interoperability and prior-authorization mandates.

4 | UnitedHealthcare Pledges to Cut Prior Authorizations by Another Third in 2026 | Commercial

UnitedHealthcare said it will eliminate roughly another 30% of its remaining prior-authorization requirements by the end of 2026, including select outpatient surgeries, some diagnostic tests such as echocardiograms, and certain outpatient therapies and chiropractic care. The insurer says prior authorization now applies to about 2% of its medical services, with around 92% of requests approved, usually within a day. The pledge sits alongside its Gold Card program, standardized electronic submissions, and a broader industry shift toward AI-assisted prior authorization, including CMS's WISeR model in traditional Medicare.

5 | Large Multisite Study Ties AI Scribes to Modest Time Savings and Slightly Higher Visit Volume | New Research

A JAMA study of 8,581 ambulatory clinicians across five academic health systems (Mass General Brigham, Emory, UCSF, Yale New Haven, and UC Davis) using Ambience, Nuance DAX Copilot, or Abridge found that adopting AI scribes was associated with about 13 fewer minutes of total EHR time and 16 fewer minutes of documentation time per eight scheduled patient-hours, plus roughly half an additional visit per week. The reductions were larger for frequent users and for primary care clinicians. The authors describe the effects as real but modest, and flag open questions about note quality and longer-term impact.

‍